Myelofibrosis produces a broad and often debilitating set of symptoms driven by scarring of the bone marrow, an enlarged spleen, chronic inflammation, and disrupted blood cell production. The seven symptoms most consistently tracked in clinical practice are fatigue, night sweats, itching, abdominal discomfort, pain under the left ribs, early satiety (feeling full after eating very little), and bone pain. But the reality for many people living with myelofibrosis is messier than a tidy list, and the way symptoms interact with one another and shift over time is part of what makes this disease so difficult to manage.
Fatigue Is Usually the Most Disabling Symptom
If you ask people with myelofibrosis which symptom affects their daily life the most, the answer is almost always fatigue. This is not ordinary tiredness that improves with rest. It tends to be a deep, persistent exhaustion that interferes with work, social activities, and even basic self-care. When researchers developed the first myelofibrosis-specific tool for measuring symptom severity, fatigue was treated as the central complaint and given its own validated subscale within the questionnaire.1PubMed Central. The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis
The fatigue of myelofibrosis has multiple drivers. Anemia is a major one: because the bone marrow is progressively replaced by scar tissue, it loses the ability to produce red blood cells efficiently, and fewer red blood cells means less oxygen reaching your tissues. But anemia alone does not explain the full picture. Inflammatory signaling molecules, particularly ones like IL-6 and TNF-α, are abnormally elevated in myelofibrosis and are independently linked to fatigue even when red blood cell counts are only mildly reduced.2PubMed Central. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development This means that treating the anemia sometimes helps but rarely eliminates fatigue entirely.
How an Enlarged Spleen Creates a Cascade of Abdominal Problems
In myelofibrosis, the spleen often takes over some of the blood-cell production that the failing bone marrow can no longer handle. That extra workload causes the spleen to enlarge, sometimes dramatically. A normal spleen weighs roughly 150 grams. In advanced myelofibrosis, spleens weighing over 1,500 grams have been documented.3PubMed Central. Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension A spleen that large physically crowds other organs in the abdomen, and the downstream effects are felt as a cluster of related symptoms.
In a retrospective review of U.S. patients with myelofibrosis, those with documented splenomegaly were far more likely to report left-sided abdominal pain or discomfort (about 85% versus 37% without splenomegaly), early satiety (79% versus 47%), generalized abdominal pain (67% versus 50%), and night sweats (65% versus 50%).4Wiley Online Library (Cancer Medicine). Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review Early satiety is particularly troublesome because it can lead to unintentional weight loss and nutritional deficiencies over time. The enlarged spleen presses against the stomach, making it physically impossible to eat a normal-sized meal.
In severe cases, splenomegaly also raises pressure in the portal vein, which carries blood from the digestive organs to the liver. Portal hypertension can cause fluid to accumulate in the abdomen (ascites) and enlarge veins in the esophagus, creating a risk of serious gastrointestinal bleeding.5PubMed Central. Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension These complications are relatively uncommon, but they are life-threatening when they occur, and they are driven by the same spleen enlargement that causes the more everyday discomfort of bloating and fullness.
Constitutional Symptoms and the Role of Inflammation
Night sweats, fevers, and unintended weight loss are grouped under the term “constitutional symptoms” because they reflect a systemic process rather than a problem in one specific organ. In myelofibrosis, these symptoms are driven largely by an overactive inflammatory response. The abnormal bone marrow cells in myelofibrosis pump out high levels of inflammatory cytokines, and those signaling molecules circulate through the body and disrupt normal temperature regulation, metabolism, and sleep.6PubMed Central. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Night sweats in myelofibrosis can be severe enough to require changing bedsheets, and they tend to worsen quality of sleep in a way that compounds the fatigue. Fevers are sometimes low-grade and persistent rather than dramatic, making them easy to dismiss. Weight loss occurs both because inflammatory cytokines increase the body’s metabolic rate and because the enlarged spleen limits food intake. Taken together, these constitutional symptoms are a major reason why people with myelofibrosis sometimes look and feel generally unwell even before their blood counts have deteriorated significantly.
Bone Pain and Skeletal Involvement
The bone marrow in myelofibrosis undergoes fibrosis, meaning normal blood-forming tissue is progressively replaced by scar-like tissue. That process does not stay invisible. Bone pain is one of the seven core symptoms tracked in clinical trials, and it can range from a dull ache to sharp, localized pain.7PubMed Central. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials
A systematic review of bone lesions in primary myelofibrosis found that bone involvement can take several forms beyond marrow fibrosis, including osteosclerosis (abnormal hardening of bone) and occasionally osteolytic lesions (areas of bone destruction). The most commonly affected sites were the spine, pelvis, and ribs. The vast majority of these lesions were painful, and they tended to appear in patients over 50 with more advanced disease, where treatment options become more limited.8PubMed Central. Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review For some people, bone pain is the symptom that first brings them to a doctor, especially when it occurs in unusual locations or does not respond to typical pain management.
Itching That Water Makes Worse
Pruritus, or persistent itching, is a symptom that many people outside the myelofibrosis community would not associate with a blood cancer. Yet it is common enough to be one of the seven symptoms formally tracked in clinical trials.9PubMed Central. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials In myeloproliferative neoplasms more broadly, the itching often has a distinctive trigger: contact with water. This phenomenon, called aquagenic pruritus, can be provoked by a bath, a shower, a swim, or even sweating. People describe it as itching, burning, pricking, or stinging, typically affecting the arms, legs, and trunk.10MPN Voice. Itchy skin
The exact mechanism behind aquagenic pruritus in myelofibrosis is not fully understood, though it is thought to involve mast cells and the same inflammatory cytokines responsible for constitutional symptoms. What makes it especially frustrating is that it can turn routine hygiene into a dreaded event. Some patients report avoiding showers or limiting bathing frequency, which adds a social and psychological burden on top of the physical discomfort. Antihistamines sometimes help, but the itching can be stubbornly resistant to standard treatments.
Bleeding and Clotting Risks
Myelofibrosis disrupts the normal production and function of platelets, the blood cells responsible for clotting. This creates a paradox that catches many people off guard: the disease raises the risk of both excessive bleeding and dangerous blood clots. Easy bruising, nosebleeds, and bleeding gums are common on the bleeding side, while deep vein thrombosis and stroke are among the clotting complications.
A review of vascular complications in myelofibrosis found that thrombotic events occur at rates roughly comparable to those seen in essential thrombocythemia but less frequently than in polycythemia vera, two related blood cancers. Bleeding events, on the other hand, are relatively more common in myelofibrosis than in either of those conditions.11PubMed Central. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review The reason the risk goes both directions is that platelet counts in myelofibrosis can be either abnormally high or abnormally low depending on the stage and subtype of the disease, and even when counts are normal, the platelets themselves may not function properly.
Rare Complications That Catch Patients Off Guard
When the bone marrow can no longer produce enough blood cells, the body sometimes tries to compensate by producing them in organs that do not normally do that job, a process called extramedullary hematopoiesis. The spleen and liver are the usual sites, but blood cell production can occasionally set up shop in more unexpected locations. There are documented cases of extramedullary hematopoiesis occurring along the spinal cord, where the growing tissue can compress nerves and cause neurological symptoms like weakness or numbness in the legs.12PubMed. Imaging of spinal cord compression due to thoracic extramedullary haematopoiesis in myelofibrosis These cases are rare, but they illustrate how the effects of myelofibrosis can show up far from the bone marrow itself.
Cough is another symptom that surprises some patients. It is not caused by a respiratory infection but rather by the massively enlarged spleen pushing upward against the diaphragm, irritating the nerve that runs through it. The original myelofibrosis symptom assessment form specifically included cough from diaphragmatic irritation as one of the spleen-related symptoms worth tracking.13PubMed Central. The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis
Depression and the Symptom Burden Spiral
The relationship between myelofibrosis symptoms and mental health runs deeper than “chronic illness makes people sad.” A study of patients with myeloproliferative neoplasms found that those screening positive for depressive symptoms reported substantially worse scores on every single physical symptom measured, including fatigue, pain, and night sweats. The mean total symptom score for patients with significant depressive symptoms was about 41 on a standardized scale, compared to roughly 25 for those without, and their worst fatigue scores averaged nearly 8 out of 10 versus under 6.14Cancer Medicine. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
It is difficult to untangle cause from effect here. Chronic fatigue, disrupted sleep from night sweats, restricted eating, persistent itching, and the psychological weight of living with a cancer diagnosis all contribute to depression. At the same time, depression amplifies pain perception and fatigue, creating a feedback loop. This matters practically because treating depression, whether through therapy, medication, or support networks, can meaningfully improve how patients experience their physical symptoms even when the underlying disease has not changed.
How Symptoms Respond to Treatment
The introduction of JAK inhibitors transformed symptom management in myelofibrosis. In the landmark COMFORT-I trial, about 46% of patients receiving ruxolitinib achieved at least a 50% improvement in their total symptom score at 24 weeks, compared with just over 5% of patients receiving placebo. Spleen volume also decreased substantially, and the degree of spleen shrinkage correlated with improvements in fatigue, overall health, and quality of life.15PubMed Central. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis The vast majority of patients who achieved that symptom improvement described their condition as “much improved” or “very much improved” on a patient-reported scale.16PubMed Central. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
That said, JAK inhibitor therapy does not work equally well for everyone. Symptom responses vary, and some patients see their improvement fade over time.17PubMed Central. Ruxolitinib for Myelofibrosis – An Update of Its Clinical Effects Anemia is a particular challenge: ruxolitinib can actually worsen it in some patients, which is one reason newer JAK inhibitors have been developed with anemia specifically in mind. Momelotinib, for instance, has shown a meaningful advantage in improving hemoglobin levels compared to another JAK inhibitor, pacritinib, likely because it also blocks a pathway involved in iron regulation.18PubMed Central. Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis19PubMed Central. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
For patients with massive spleens who do not respond adequately to drug therapy, spleen-directed interventions remain an option. Splenectomy can improve symptoms and reduce the need for blood transfusions, but it carries meaningful surgical risk and long-term complications. Splenic irradiation, where low doses of radiation are aimed at the spleen to shrink it, can provide temporary relief — symptoms improved in the majority of treated patients in small studies — but the effect tends to be short-lived and carries its own risk of worsening blood counts.20PubMed. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma21PubMed. Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?
What Happens to Symptoms After a Stem Cell Transplant
Allogeneic stem cell transplant is the only treatment that can potentially cure myelofibrosis, but it is an intense procedure reserved for younger or fitter patients with high-risk disease. A reasonable question is whether this aggressive treatment actually makes symptoms better.
The answer is complicated. A study tracking symptom burden before and after transplant found that the overall total symptom score did not change dramatically at the one-year mark, with a baseline average of 28 and a one-year average of about 24. However, the myelofibrosis-specific symptoms — itching, night sweats, bone pain, and fever — did show meaningful improvement at various time points after the transplant.22PubMed Central. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis The reason the total score stays relatively flat is that transplant introduces its own set of symptoms and complications, including fatigue, graft-versus-host disease, and infection risk, which offset the relief from the disease-specific ones. Patients going into a transplant should understand that while the disease-driven symptoms tend to improve, the overall experience of feeling unwell does not necessarily lift quickly.
How Myelofibrosis Differs in Children and Young Adults
Myelofibrosis is overwhelmingly a disease of older adults, with most patients diagnosed after age 60. When it occurs in children or young adults, it appears to be a genuinely different entity. A large analysis of pediatric primary myelofibrosis found distinct clinical, blood-count, bone marrow, and molecular features compared to adult disease.23PubMed. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis–an entity different from adults Among pediatric and young adult patients with myeloproliferative neoplasms more broadly, myelofibrosis accounted for only about 5% of cases, compared to roughly 15% in adults, and the time to disease transformation tended to be longer.24Blood. Myeloproliferative Neoplasms in Pediatrics and Young Adults: Genetic Lesions, Diagnostic Features, and Clinical Outcomes
For families dealing with a pediatric diagnosis, the practical implication is that adult symptom profiles and treatment guidelines may not apply directly. The disease tends to behave differently enough that management should be guided by specialists experienced with childhood myeloproliferative neoplasms rather than extrapolating from the adult literature.
How Symptoms Are Formally Tracked
If you are being treated for myelofibrosis, you will likely be asked to fill out a symptom questionnaire at regular intervals. The most widely used version asks you to rate seven core symptoms — fatigue, night sweats, itching, abdominal discomfort, left-side rib pain, early satiety, and bone pain — on a scale from 0 (absent) to 10 (worst imaginable).25PubMed Central. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials This tool was developed specifically because symptoms in myelofibrosis are so central to how the disease affects daily life, and because treatment decisions often hinge on whether symptoms are getting better or worse.
The scores matter beyond your individual care. They are the primary way clinical trials measure whether a new drug is actually helping. In the pivotal studies that led to approval of JAK inhibitors, a 50% or greater reduction in total symptom score was one of the key endpoints.26PubMed Central. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis Being honest and specific when filling out these forms directly influences the treatment recommendations you receive and the future of drug development for the disease.